ContraFect is a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA), including lysins and amurin peptides, as new medical modalities for the treatment of antibiotic-resistant infections. Co.'s main DLA product candidate, exebacase, is being developed in patients with chronic prosthetic joint infections of the knee due to S. aureus or coagulase-negative Staphylococci. Co.'s other product candidate, CF-370, is designed to target gram-negative bacteria, including P. aeruginosa, K. pneumoniae and A. baumannii, and is effective in vivo activity against these pathogens, even against multidrug-resistant and extensively drug-resistant strains. The CFRX average annual return since 2014 is shown above.
The Average Annual Return on the CFRX average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CFRX average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CFRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|